Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022

MELBOURNE, Australia and KING OF PRUSSIA, Pennsylvania Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL’s three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the decades ahead.

Related Keywords

Germany ,Australia ,United States ,Broadmeadows ,New South Wales ,Massachusetts ,Melbourne ,Victoria ,Waltham ,Switzerland ,Andrew Nash ,Greg Healy ,Kim Odonohue ,Jimmy Baker ,Stage Development Includes Disruptive Innovation ,Breakthrough Victoria Fund ,University Of Melbourne ,European Medicines Agency ,Drug Administration ,Translational Sciences ,Fresenius Medical Care ,New Additions ,Biotech Manufacturing ,Arcturus Therapeutics ,Bill Mezzanotte ,Executive Vice President ,Chief Medical Officer ,External Innovation ,Biotechnology Incubator ,Australia Names Its ,Cicada Innovations ,Melbourne Biomedical ,Victorian Government ,Scientific Officer ,Senior Vice President ,Breakthrough Victoria ,Biotechnology ,Food And Drug Administration ,Infection ,Influenza ,Manufacturing ,Vaccine ,Branches Of Biology ,Clazakizumab ,Csl Behring ,Csl Limited ,Gene Therapy ,Hereditary Angioedema ,